Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
$329.99
$12.58B1.18832,048 shsN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.44
$1.23
$0.98
$1.60
$1.09B1.52.70 million shs2.22 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.42
+0.9%
$23.56
$18.80
$27.64
$921.58M0.29738,185 shs275,901 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+0.70%+2.86%+26.32%+23.71%+4.35%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+1.53%+4.31%+0.26%+1.66%-8.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
$329.99
$12.58B1.18832,048 shsN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.44
$1.23
$0.98
$1.60
$1.09B1.52.70 million shs2.22 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.42
+0.9%
$23.56
$18.80
$27.64
$921.58M0.29738,185 shs275,901 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+0.70%+2.86%+26.32%+23.71%+4.35%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+1.53%+4.31%+0.26%+1.66%-8.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00
N/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.557.64% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.29
Hold$29.4025.53% Upside

Current Analyst Ratings Breakdown

Latest KRTX, OPK, and PCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
UpgradeSell (D)Sell (D+)
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/4/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeSell (D-)Sell (E+)
5/1/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Boost Price TargetSector Perform$22.00 ➝ $24.00
5/1/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Boost Price TargetBuy$30.00 ➝ $32.00
4/29/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeOutperformMarket Perform
4/21/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingSell (D-)
4/7/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
UpgradeStrong SellHold
3/26/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Lower Price TargetEqual Weight$27.00 ➝ $25.00
(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.79N/AN/A$1.67 per share0.86
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$726.41M1.27$3.95 per share5.93$16.11 per share1.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.12195.188.77N/A0.70%10.24%5.47%8/4/2026 (Estimated)

Latest KRTX, OPK, and PCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.61$0.60-$0.01$0.07$171.80 million$177.38 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.56
4.73
3.35

Institutional Ownership

CompanyInstitutional Ownership
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%

Insider Ownership

CompanyInsider Ownership
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
13.20%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million379.89 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72039.35 million36.83 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Karuna Therapeutics stock logo

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.44 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 -0.02 (-1.46%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.42 +0.21 (+0.90%)
Closing price 04:00 PM Eastern
Extended Trading
$23.40 -0.02 (-0.06%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.